Table II.
Common (≥2%) Adverse Events During 6 Weeks of Treatment With Placebo or Active Therapy
| Category | Placebo (n=95) | Nebivolol (n=188) | Lisinopril (n=189) | Nebivolol + Lisinopril (n=189) |
|---|---|---|---|---|
| n (%) | ||||
| Patients with at least one adverse event | 29 (30.5) | 51 (27.1) | 58 (30.7) | 57 (30.7) |
| Upper respiratory tract infection | 3 (3.2) | 6 (3.2) | 5 (2.6) | 7 (3.7) |
| Headache | 7 (7.4) | 5 (2.7) | 6 (3.2) | 6 (3.2) |
| Bradycardia | 0 | 4 (2.1) | 0 | 4 (2.1) |
| Nasopharyngitis | 1 (1.1) | 8 (4.3) | 5 (2.6) | 4 (2.1) |
| Cough | 1 (1.1) | 4 (2.1) | 6 (3.2) | 3 (1.6) |
| Fatigue | 1 (1.1) | 6 (3.2) | 1 (0.5) | 3 (1.6) |
| Dizziness | 2 (2.1) | 2 (1.1) | 3 (1.6) | 2 (1.1) |
| Nasal congestion | 1 (1.1) | 1 (0.5) | 4 (2.1) | 1 (0.5) |
| Neck pain | 2 (2.1) | 0 | 0 | 0 |
| Sinus congestion | 1 (1.1) | 0 | 6 (3.2) | 0 |